ALTAltimmune, Inc.

Nasdaq altimmune.com


$ 7.72 $ 0.56 (7.82 %)    

Thursday, 09-May-2024 15:59:56 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 7.72
$ 7.30
$ 0.00 x 0
$ 0.00 x 0
$ 7.30 - $ 8.07
$ 2.09 - $ 14.84
4,552,417
na
546.59M
$ 0.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 04-01-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 04-02-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-03-2017 03-31-2017 10-Q
30 03-14-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 03-11-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 03-11-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jim-cramer-calls-nutanix-the-perfect-enterprise-software-company-for-the-moment

Cramer discusses Agnico Eagle Mines, Nutanix, Altimmune, CVR Energy and Quanta Services on CNBC's "Mad Money."

 guggenheim-downgrades-altimmune-to-neutral

Guggenheim analyst Seamus Fernandez downgrades Altimmune (NASDAQ:ALT) from Buy to Neutral.

 hc-wainwright--co-maintains-buy-on-altimmune-lowers-price-target-to-12

HC Wainwright & Co. analyst Patrick Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target fro...

 why-kodiak-sciences-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

 b-riley-securities-reiterates-buy-on-altimmune-maintains-20-price-target

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $20 price target.

 rex-american-resources-reports-upbeat-earnings-joins-avalo-therapeutics-rh-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corpo...

 why-is-obesity-drug-developer-altimmune-stock-trading-lower-on-wednesday

Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipos...

 altimmune-q4-gaap-eps-054-misses-043-estimate-sales-3700k-up-from-11000k-yoy

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.43) by...

 earnings-scheduled-for-march-27-2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...

 altimmunes-earnings-outlook
Altimmune's Earnings Outlook
03/26/2024 15:00:59

 cramer-calls-datadog-dynamite-puts-sofi-in-dog-house-what-the-heck-is-going-on

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION